Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

Passive income investors looking to get paid to navigate a more turbulent stock market should look to the many dividend ...

Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dolsten, who served as Pfizer’s chief scientific officer and ...